---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037979"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2026-08-14T11:35:47+00:00"
generated_at: "2026-08-14T11:40:32.458280+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off

## Summary
- Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.
- Cash $7.4M at June 30, 2026; raised $4.4M gross from May 14 registered direct offering.
- LP-300 HARMONIC: median PFS 8.9 mo in L858R patients completing 6 cycles (n=9) vs 8.4 mo overall (n=16); HR 0.37; FDA cleared protocol amendments to focus on L858R and extend to 8 cycles.
- EMA cleared LP-184 Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark; FDA cleared TNBC trial; USPTO Notice of Allowance for three-gene signature.
- Open Medicine AI established as separate company with executed commercial licenses; plans to raise capital at OMAI level.

## SEC filing metadata
- accession: 0001493152-26-037979
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2026-08-14T11:35:47+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/0001493152-26-037979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037979
- JSON: https://secwatch.observer/filing/0001493152-26-037979.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.